These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

502 related articles for article (PubMed ID: 22108651)

  • 1. [(35)S]GTPγS binding and opioid tolerance and efficacy in mouse spinal cord.
    Madia PA; Navani DM; Yoburn BC
    Pharmacol Biochem Behav; 2012 Mar; 101(1):155-65. PubMed ID: 22108651
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stimulation of guanosine-5'-o-(3-[35S]thio)triphosphate binding in digitonin-permeabilized C6 rat glioma cells: evidence for an organized association of mu-opioid receptors and G protein.
    Alt A; McFadyen IJ; Fan CD; Woods JH; Traynor JR
    J Pharmacol Exp Ther; 2001 Jul; 298(1):116-21. PubMed ID: 11408532
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Absence of G-protein activation by mu-opioid receptor agonists in the spinal cord of mu-opioid receptor knockout mice.
    Narita M; Mizoguchi H; Narita M; Sora I; Uhl GR; Tseng LF
    Br J Pharmacol; 1999 Jan; 126(2):451-6. PubMed ID: 10077238
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Opioid agonist efficacy predicts the magnitude of tolerance and the regulation of mu-opioid receptors and dynamin-2.
    Pawar M; Kumar P; Sunkaraneni S; Sirohi S; Walker EA; Yoburn BC
    Eur J Pharmacol; 2007 Jun; 563(1-3):92-101. PubMed ID: 17349996
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mu-opioid receptors are involved in the tolerance to nicotine antinociception.
    Galeote L; Kieffer BL; Maldonado R; Berrendero F
    J Neurochem; 2006 Apr; 97(2):416-23. PubMed ID: 16539669
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Opioid agonist and antagonist treatment differentially regulates immunoreactive mu-opioid receptors and dynamin-2 in vivo.
    Yoburn BC; Purohit V; Patel K; Zhang Q
    Eur J Pharmacol; 2004 Sep; 498(1-3):87-96. PubMed ID: 15363980
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Loss of TRPV1-expressing sensory neurons reduces spinal mu opioid receptors but paradoxically potentiates opioid analgesia.
    Chen SR; Pan HL
    J Neurophysiol; 2006 May; 95(5):3086-96. PubMed ID: 16467418
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Functional reduction in mu-opioidergic system in the spinal cord under a neuropathic pain-like state following chronic ethanol consumption in the rat.
    Narita M; Miyoshi K; Narita M; Suzuki T
    Neuroscience; 2007 Feb; 144(3):777-82. PubMed ID: 17156932
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of [Dmt1]DALDA and DAMGO in binding and G protein activation at mu, delta, and kappa opioid receptors.
    Zhao GM; Qian X; Schiller PW; Szeto HH
    J Pharmacol Exp Ther; 2003 Dec; 307(3):947-54. PubMed ID: 14534366
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of cAMP-dependent protein kinase (PKA) in opioid agonist-induced mu-opioid receptor downregulation and tolerance in mice.
    Shen J; Benedict Gomes A; Gallagher A; Stafford K; Yoburn BC
    Synapse; 2000 Dec; 38(3):322-7. PubMed ID: 11020235
    [TBL] [Abstract][Full Text] [Related]  

  • 11. mu-Opioid receptor internalization-dependent and -independent mechanisms of the development of tolerance to mu-opioid receptor agonists: Comparison between etorphine and morphine.
    Narita M; Suzuki M; Narita M; Niikura K; Nakamura A; Miyatake M; Yajima Y; Suzuki T
    Neuroscience; 2006; 138(2):609-19. PubMed ID: 16417975
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of chronic ethanol and withdrawal on the mu-opioid receptor- and 5-Hydroxytryptamine(1A) receptor-stimulated binding of [(35)S]Guanosine-5'-O-(3-thio)triphosphate in the fawn-hooded rat brain: A quantitative autoradiography study.
    Chen F; Lawrence AJ
    J Pharmacol Exp Ther; 2000 Apr; 293(1):159-65. PubMed ID: 10734165
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Involvement of spinal protein kinase Cgamma in the attenuation of opioid mu-receptor-mediated G-protein activation after chronic intrathecal administration of [D-Ala2,N-MePhe4,Gly-Ol(5)]enkephalin.
    Narita M; Mizoguchi H; Narita M; Nagase H; Suzuki T; Tseng LF
    J Neurosci; 2001 Jun; 21(11):3715-20. PubMed ID: 11356858
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modulation by mu-opioid agonists of guanosine-5'-O-(3-[35S]thio)triphosphate binding to membranes from human neuroblastoma SH-SY5Y cells.
    Traynor JR; Nahorski SR
    Mol Pharmacol; 1995 Apr; 47(4):848-54. PubMed ID: 7723747
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Opioid peptide receptor studies. 17. Attenuation of chronic morphine effects after antisense oligodeoxynucleotide knock-down of RGS9 protein in cells expressing the cloned Mu opioid receptor.
    Xu H; Wang X; Wang J; Rothman RB
    Synapse; 2004 Jun; 52(3):209-17. PubMed ID: 15065220
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of the binding of [3H][Dmt1]H-Dmt-D-Arg-Phe-Lys-NH2, a highly potent opioid peptide.
    Neilan CL; Janvey AJ; Bolan E; Berezowska I; Nguyen TM; Schiller PW; Pasternak GW
    J Pharmacol Exp Ther; 2003 Aug; 306(2):430-6. PubMed ID: 12663687
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ultra-low-dose naloxone suppresses opioid tolerance, dependence and associated changes in mu opioid receptor-G protein coupling and Gbetagamma signaling.
    Wang HY; Friedman E; Olmstead MC; Burns LH
    Neuroscience; 2005; 135(1):247-61. PubMed ID: 16084657
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Spinal interaction between the highly selective μ agonist DAMGO and several δ opioid receptor ligands in naive and morphine-tolerant mice.
    Brain Res Bull; ; . PubMed ID: 22995282
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 26.